Globally, glaucoma affects an estimated 76 million people (≈1 % of the world’s population), and it is the leading cause of irreversible blindness worldwide [WHO, 2023]. In the United States, about 3 million adults have glaucoma, and an additional 2.7 million have suspected disease that may progress without treatment [CDC, 2022].

Symptoms

Glaucoma is often called the “silent thief of sight” because many people experience no symptoms until peripheral vision is already lost. Below is a comprehensive symptom list, noting which type of glaucoma they most commonly accompany.

Primary Open‑Angle Glaucoma (POAG)

• Gradual peripheral vision loss – may be noticed when bumping into objects on the sides.
• Blurred vision in dim lighting.
• Halos around lights – usually subtle and mistaken for cataract changes.
• Eye fatigue after prolonged reading.

Primary Angle‑Closure Glaucoma (PACG)

• Painful red eye – sudden onset.
• Severe headache, often described as “behind the eyes”.
• Nausea and vomiting – can mimic migraine.
• Blurred vision or sudden loss of vision in one eye.
• Halos around lights, especially at night.

Secondary Glaucoma (e.g., steroid‑induced, neovascular)

• Similar to POAG/PACG but may appear after eye surgery, trauma, or as a complication of systemic disease (e.g., diabetes).
• Noticeable “cloudy” vision if cataract formation co‑exists.

Causes and Risk Factors

Glaucoma results from impaired outflow of aqueous humor, the clear fluid that nourishes the eye. When drainage (via the trabecular meshwork or uveoscleral pathway) is blocked or slowed, pressure inside the eye rises, compressing the optic nerve fibers.

Primary Causes

• Elevated intraocular pressure (IOP) – the single most important modifiable risk factor.
• Anatomical blockage of the drainage angle (angle‑closure).
• Genetic mutations affecting trabecular meshwork function (MYOC, OPTN genes).

Risk Factors

• Age: risk doubles every decade after age 40.
• Family history: first‑degree relatives have a 4‑to‑9‑fold increased risk.
• Ethnicity: POAG is most common in African‑American adults (≈5‑6 % over 70 y); PACG is more frequent in East Asian and Inuit populations.
• High myopia (nearsightedness ≥ −6 diopters) increases POAG risk.
• Thin central corneal thickness (≤ 540 µm) predicts faster progression.
• Systemic conditions: uncontrolled diabetes, hypertension, and cardiovascular disease.
• Medication use: prolonged corticosteroid therapy (topical, oral, or inhaled).
• Eye injuries or surgeries (e.g., cataract extraction complications).

Diagnosis

Because early glaucoma may be asymptomatic, routine eye exams are essential, especially for high‑risk groups.

Key Diagnostic Tests

• Tonometry – measures IOP. Normal range: 10‑21 mm Hg. Values > 21 mm Hg warrant further evaluation.
• Gonioscopy – visualizes the drainage angle with a special contact lens; distinguishes open vs. closed angles.
• Ophthalmoscopy (or fundus photography) – assesses optic‑nerve head for cupping, rim thinning, or hemorrhages.
• Optical Coherence Tomography (OCT) – provides high‑resolution images of retinal nerve fiber layer (RNFL) thickness; early thinning predicts progression.
• Visual field testing (perimetry) – detects functional loss, especially peripheral field defects.
• Corneal pachymetry – measures corneal thickness to adjust IOP interpretation.

Diagnosis is typically based on a combination of elevated IOP, optic‑nerve changes, visual‑field defects, and angle assessment. A single test rarely confirms or excludes glaucoma.

Treatment Options

The goal of therapy is to lower IOP to a level that prevents further optic‑nerve damage while preserving quality of life.

Medications

• Prostaglandin analogs (e.g., latanoprost, bimatoprost) – increase uveoscleral outflow; once‑daily dosing, first‑line for most patients.
• Beta‑blockers (e.g., timolol, betaxolol) – decrease aqueous production; avoid in patients with asthma or heart block.
• Alpha‑agonists (e.g., brimonidine) – both reduce production and increase outflow; may cause dry mouth.
• Carbonic anhydrase inhibitors (e.g., dorzolamide, oral acetazolamide) – lower production; systemic side effects include tingling and metabolic acidosis.
• Rho‑kinase inhibitors (e.g., netarsudil) – novel class that enhances trabecular outflow.

Medication adherence is crucial—up to 50 % of patients miss doses, increasing progression risk [Cleveland Clinic, 2022].

Surgical and Laser Procedures

• Laser trabeculoplasty (SLT or ALT) – improves trabecular outflow; often used when medications insufficient.
• Minimally invasive glaucoma surgery (MIGS) – inserts tiny stents (e.g., iStent) to bypass resistance; appropriate for mild‑to‑moderate disease.
• Trabeculectomy – creates a new drainage pathway under a scleral flap; considered the “gold standard” for advanced glaucoma.
• Glaucoma drainage implants (e.g., Ahmed, Baerveldt) – tube shunts that divert fluid to an external reservoir; reserved for refractory cases.
• Cyclophotocoagulation – laser ablation of ciliary body to reduce fluid production; used in end‑stage disease.

Lifestyle and Adjunct Measures

• Regular aerobic exercise (e.g., walking, swimming) can lower IOP by 2‑4 mm Hg [Mayo Clinic, 2021].
• Limit caffeine intake (> 300 mg/day may transiently raise IOP).
• Avoid activities that increase head‑down pressure (e.g., inverted yoga poses) if you have angle‑closure risk.
• Stay hydrated; extreme dehydration can thicken the aqueous humor, worsening pressure.

Living with Intraocular Pressure Glaucoma

Managing glaucoma is a lifelong commitment. Below are practical tips to integrate care into daily life.

• Medication routine: Pair eye‑drops with a daily habit (e.g., brushing teeth). Use a preset alarm or a pill‑box‑style eye‑drop dispenser.
• Regular follow‑up: Schedule eye exams every 3‑6 months for early‑stage disease; more frequent visits may be needed after surgery.
• Eye‑drop technique: Wash hands, tilt head back, pull lower lid down, apply one drop, close eye gently for 1‑2 minutes, and press the inner canthus to reduce systemic absorption.
• Protect your eyes: Wear UV‑blocking sunglasses and safety glasses during sports or when working with tools.
• Driving safety: If peripheral vision is compromised, avoid night driving and consider a “visual field report” for insurance/DMV if required.
• Nutrition: Diets rich in leafy greens, omega‑3 fatty acids, and antioxidants may support optic‑nerve health—though evidence is modest.
• Stress management: Chronic stress can raise blood pressure, indirectly affecting ocular perfusion. Practice relaxation techniques.

Prevention

While you cannot change genetics or age, several evidence‑based steps can lower your risk or delay onset.

• Annual comprehensive eye exams after age 40 (earlier if you have risk factors).
• Control systemic conditions—maintain blood pressure < 130/80 mm Hg, keep HbA1c < 7 % if diabetic.
• Limit steroid exposure: Use the lowest effective dose and discontinue when possible under physician guidance.
• Healthy lifestyle: Regular exercise, balanced diet, and smoking cessation decrease overall vascular risk.
• Protective eye care after trauma: Seek immediate evaluation after blunt eye injuries.
• Family screening: First‑degree relatives should have baseline IOP and optic‑nerve imaging by age 30–40.

Complications

If left untreated or inadequately controlled, glaucoma can lead to serious outcomes.

• Permanent vision loss – usually starts peripherally and progresses to central vision, potentially resulting in blindness.
• Reduced quality of life – difficulties with driving, reading, and mobility increase risk of falls.
• Psychological impact – anxiety, depression, and social isolation are common in patients with progressive vision loss.
• Surgical complications – infection, bleb failure, hypotony (excessively low IOP), or cataract formation after glaucoma surgery.

When to Seek Emergency Care

---

**Sources**: Mayo Clinic, CDC, NIH National Eye Institute, World Health Organization, Cleveland Clinic, peer‑reviewed ophthalmology journals (e.g., *Ophthalmology*, *JAMA Ophthalmology*). All information reflects current knowledge as of June 2026 and is intended for educational purposes—not a substitute for professional medical advice.